Exubera Approval in US

RNS Number:6001X
Bespak PLC
30 January 2006


For immediate release                                           30 January 2006



Bespak plc



        Welcomes regulatory approval of Exubera(R) in the United States

Bespak plc (LSE: BPK), a leader in specialty medical devices, is pleased to note
that Pfizer Inc announced on Friday evening, 27 January 2006, that the United
States Food and Drug Administration (FDA) has approved Exubera (inhaled human
insulin) for the treatment of adults with type 1 and type 2 diabetes.  This
follows approval by the European Commission last Thursday.

Exubera, which is expected to be available for patients by mid-year, is the
first inhaled form of insulin and the first insulin option that does not need to
be administered by injection in the United States.

Bespak, in conjunction with Nektar Therapeutics, has developed the manufacturing
process for Exubera's inhaler, which the Company will manufacture at its purpose
designed facility in Milton Keynes.  The inhaler produces in its chamber a cloud
of insulin powder, which is designed to pass rapidly into the bloodstream to
regulate the body's blood sugar levels.

Mark Throdahl, Bespak's Chief Executive, said: "We are delighted that both the
US and European filings have been approved and we look forward to participating
in the commercial success of Exubera by supplying the inhaler device."




For further information please call:


Bespak plc
Mark Throdahl - Chief Executive                         [phone]
Martin Hopcroft - Group Finance Director

Buchanan Communications                                    [phone]
Tim Thompson / Mark Court / Mary-Jane Johnson





Notes for Editors:



About Bespak plc

Bespak, a leader in specialty medical devices, develops delivery systems for the
pharmaceutical industry and disposable airway management products for critical
care settings.  Bespak's product range includes metered dose and dry powder
inhalers, actuators, inflation valves, disposable face masks, breathing circuits
and laryngeal tubes.  The group, which has facilities in King's Lynn and Milton
Keynes in the UK and Indianapolis and Kent, Ohio, in the US, is quoted on the
Official List of the London Stock Exchange (LSE: BPK).  For more information,
please visit www.bespak.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCAKCKPCBKDCDB